AC Immune (ACIU) Enterprise Value (2014 - 2026)

AC Immune (ACIU) has 13 years of Enterprise Value data on file, last reported at -$95.5 billion in Q1 2026.

• On a quarterly basis, Enterprise Value fell 58875.4% year-over-year to -$95.5 billion in Q1 2026; TTM through Mar 2026 was -$95.5 billion, a 58875.4% decrease from a year earlier, with the FY2025 full-year figure at -$78.0 billion, down 41173.1% from the prior year.
• Enterprise Value for Q1 2026 stood at -$95.5 billion, down from -$80.9 billion in the prior quarter.
• Over the last five years, Enterprise Value for ACIU reached as high as $78.1 million in Q4 2024 and fell as low as -$125.6 billion in Q1 2022.
• Historically, Enterprise Value has averaged -$23.4 billion across 5 years, with a median of -$153.6 million in 2025.
• Across the five-year window, Enterprise Value surged 147.77% in 2024 and slumped 103709.13% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$127.2 million in 2022, then declined by 28.41% to -$163.4 million in 2023, then jumped by 147.77% to $78.1 million in 2024, then slumped by 103709.13% to -$80.9 billion in 2025, then dropped by 18.1% to -$95.5 billion in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$95.5 billion in Q1 2026, -$80.9 billion in Q4 2025, and -$135.6 million in Q3 2025.